JPS6338163A - Method for measuring antigen - Google Patents
Method for measuring antigenInfo
- Publication number
- JPS6338163A JPS6338163A JP18193386A JP18193386A JPS6338163A JP S6338163 A JPS6338163 A JP S6338163A JP 18193386 A JP18193386 A JP 18193386A JP 18193386 A JP18193386 A JP 18193386A JP S6338163 A JPS6338163 A JP S6338163A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- insulin
- hapten
- antibody
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 38
- 102000036639 antigens Human genes 0.000 title claims abstract description 38
- 108091007433 antigens Proteins 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 30
- 239000002253 acid Substances 0.000 claims abstract description 8
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 5
- 239000012085 test solution Substances 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 13
- 238000005259 measurement Methods 0.000 abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 230000002378 acidificating effect Effects 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 abstract description 2
- 229910017604 nitric acid Inorganic materials 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 abstract description 2
- 210000003296 saliva Anatomy 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 54
- 229940125396 insulin Drugs 0.000 description 36
- 102000004877 Insulin Human genes 0.000 description 18
- 108090001061 Insulin Proteins 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 102000013415 peroxidase activity proteins Human genes 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 108091006587 SLC13A5 Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は抗原に対する抗体が存在する試料中の該抗原の
簡便な測定方法に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a simple method for measuring an antigen in a sample in which antibodies against the antigen are present.
血清などの体液中の各種の抗原及びハプテン?測定する
ことは、疾患の診断を行う臨床検査上重要である。しか
し、血清などの体液中には、該抗原又はハプテンに対す
る抗体がしばしば存在し、該抗原及び該ハプテンの測定
を困稚にしている。該抗原に対する抗体が存在する体液
中の抗原の測定法として抗インスリン抗体が存在する体
液中の総インスリン量の測定が報告さねている。これに
は従来2つの方法がある。その1つは、拭インスリン抗
体を含む体液からインスリンを酸性アルコールにより抽
出して測定するものである[G、M、グロドスキー(G
、 M、 Grod−sky )、P、 H,フォルジ
ャム(P、 H,Forsham )、ジャーナル・オ
ブ・クリニカル・インヴエスティゲーション(J、、C
11n、工nvest、 )、第39巻第1070頁(
1960)、L、C1,ヘディング(L。Various antigens and haptens in body fluids such as serum? Measuring is important in clinical tests for diagnosing diseases. However, antibodies against the antigen or hapten are often present in body fluids such as serum, making measurement of the antigen or hapten difficult. As a method for measuring antigens in body fluids containing antibodies against the antigen, measurement of the total amount of insulin in body fluids containing anti-insulin antibodies has not been reported. Conventionally, there are two methods for this. One method is to extract and measure insulin from body fluids containing insulin antibodies using acidic alcohol [G., M., Grodsky (G.
, M. Grod-sky), P. H. Forsham, Journal of Clinical Investigation (J., C.
11n, Engineering Best, ), Volume 39, Page 1070 (
1960), L, C1, heading (L.
G、HecLing )、ディアベトロギア(Di、a
betolo−gia )、第8巻m 260頁(19
72)10他の1つは、体液試料を酸性処理後、抗イン
スリン抗体を中和と共にポリエチレングリコールにより
沈殿除去した佼に、インスリン?測定する方法である(
酸/ポリエチレングリコール処理)CS、ナカガワ(S
、Nakagawa ) ら、ディアベテス(Dia
betes )、第22巻第590頁(1973)、H
,クズヤ(H,KuZu7a ) ら、ディアベテス
、第26巻第22頁(1977)]。G, HecLing), Diabetologia (Di, a
betolo-gia), Volume 8, page 260 (19
72) 10 Another method is to neutralize anti-insulin antibodies and precipitate them with polyethylene glycol after acidifying the body fluid sample.Insulin? It is a method of measuring (
acid/polyethylene glycol treatment) CS, Nakagawa (S
, Nakagawa) et al., Diabetes (Dia
betes), Vol. 22, p. 590 (1973), H
, Kuzuya H. et al., Diabetes, Vol. 26, p. 22 (1977)].
しかしながら、これらの方法には欠点がある。 However, these methods have drawbacks.
第1にこれらの2つの方法は共に操作が複雑である。酸
性アルコールによる抽出も、ポリエチレングリコールに
よる沈殿も複雑である。第2に、酸性アルコールで抽出
できる抗原の種類は限られており、また、ポリエチレン
グリコールで沈殿しない抗原の才1類も限られている。First, both of these two methods are complex to operate. Both extraction with acidic alcohols and precipitation with polyethylene glycol are complicated. Second, the types of antigens that can be extracted with acidic alcohol are limited, and the number of antigens that cannot be precipitated with polyethylene glycol is also limited.
本発明の目的は、前記の事情)てかんがみて、従来法に
比べて、簡便でかつ、多くの!1類の抗原及び・・ブテ
ンの測定して応用可能な抗体存在下における抗原及びハ
プテンの測定方法全提供することにある。In view of the above-mentioned circumstances, the purpose of the present invention is to be simpler and more efficient than conventional methods. The object of the present invention is to provide a complete method for measuring antigens and haptens in the presence of antibodies that can be applied to the measurement of type 1 antigens and butenes.
〔間5′八点を解決するための手段〕
本発明を概説すれば、本発明は抗体存在下における抗原
又はハプテンの61す定方法に関する発明であって、下
記の工程(A)、(B)及び(C)CA)抗原又はハプ
テンとその抗体を含有する被検液に酸を添加し、抗原性
は損わないが該抗原又はハプテンの免疫学的測定に影響
を及ぼす抗体を酸性条件下で失活させる工程
(B)該被検液を中和する工程
(C) 該被検液中の抗卓又はハプテンfJ (、免
疫学的に測定する工程
を包含することを特徴とする。[Means for solving the eight points between 5' and 5'] To summarize the present invention, the present invention relates to a method for determining an antigen or hapten in the presence of an antibody, which comprises the following steps (A) and (B). ) and (C)CA) Acid is added to the test solution containing the antigen or hapten and its antibody, and the antibody that does not impair antigenicity but affects the immunoassay of the antigen or hapten is incubated under acidic conditions. (B) neutralizing the test solution; (C) neutralizing the test solution; and (C) neutralizing the test solution.
本発明方法により測定可能な被検液の例としては血清、
血漿、髄液、唾液、尿等の体液が挙げられる。Examples of test liquids that can be measured by the method of the present invention include serum,
Examples include body fluids such as plasma, cerebrospinal fluid, saliva, and urine.
本発明の(A)工程において使用される酸には特に限定
は々く、塩酸、硝酸、硫敲、過塩素酸等が使用される。The acid used in step (A) of the present invention is not particularly limited, and examples include hydrochloric acid, nitric acid, sulfuric acid, perchloric acid, and the like.
また、抗原性は損わ々いが該抗原又jdハブテンの免疫
学的測定に影響を及ぼす抗体全失活さ亡る酸性条件は抗
原及びハプテンの種類により一定でないが、抗原がイン
スリン、成長ホルモ:/ 、甲状腺刺激ホルモン、アル
ファ・フェトプロティンなどの場合、pH15以下、好
ましくは約pH1,数十時間、4℃〜50℃の条件で目
的が達せられる。In addition, although the antigenicity is impaired, the acidic conditions that cause total inactivation of the antibody, which affects the immunoassay of the antigen or JD hapten, are not constant depending on the type of antigen and hapten, but when the antigen is insulin, growth hormone, :/ In the case of thyroid stimulating hormone, alpha-fetoprotein, etc., the purpose can be achieved at pH 15 or lower, preferably at about pH 1, and at 4°C to 50°C for several tens of hours.
本発明の(B)工程における中和において使用される塩
基には特に制限はなく、水酸化す) IJウム、水酸化
カリウム、水酸化アンモニウム等が使用される。The base used in the neutralization in step (B) of the present invention is not particularly limited, and hydroxide, potassium hydroxide, ammonium hydroxide, etc. are used.
本発明の(C)工程における抗原又はハプテンの測定法
としては、従来よく知られた種々の免疫学的測定法が用
いられる。Various well-known immunoassay methods can be used to measure the antigen or hapten in step (C) of the present invention.
以下、本発明(でよる抗原測定法を詳細に説明する。Hereinafter, the antigen measurement method according to the present invention will be explained in detail.
まず、被検液にウシ血清アルブミン(以下、BSAと略
記する)含何リン酸緩衝生理食塩水全添加し、これに塩
酸を加えpHをおよそ1とした後、室温で約60分放置
する。これ(て水酸化ナトリウムを加えて中和し、史に
BSAとNaN1 全含むリン酸緩衝生理食塩水を加
える。First, phosphate buffered saline containing bovine serum albumin (hereinafter abbreviated as BSA) is completely added to the test solution, hydrochloric acid is added to the solution to adjust the pH to approximately 1, and the solution is left at room temperature for about 60 minutes. Neutralize this by adding sodium hydroxide, and then add phosphate buffered saline containing BSA and NaN1.
このようにして調整したサンプル中の抗原量を以下の方
法によって測定する。すなわち、抗体IgG又はF (
a b’)t 5r:不溶化したプラスチック製マイ
クロタイタープレート、プラスチック裂ボール、プラス
チック製チューブ等の固相担体を上記サンプルと4℃〜
37℃で4時間〜24時間、好ましくけ57Cで4時間
反応させ、リン酸緩衝生理食塩水で洗浄後、これ?酵素
標識した抗体工gG又はそのF(ab’)1、好ましく
はそのFab’ と4℃〜37℃で4時間〜12時間
、好ましくけ20℃で4時間反応させた後、リン酸緩衝
生理食塩水で洗浄後、固相に結合した酵素活性を測定し
た。標識用酵素としてはアルカリホスファターゼ、β−
D−ガラクトシダーゼ、ペルオキシダーゼ等があり、ペ
ルオキシダーゼが適している。また、酵素の暴′t1と
してはりIJ 、’<。The amount of antigen in the sample thus prepared is measured by the following method. That is, antibody IgG or F (
a b') t 5r: Insolubilized solid phase carrier such as a plastic microtiter plate, plastic cleft ball, plastic tube, etc. with the above sample at 4°C ~
After reacting at 37°C for 4 to 24 hours, preferably at 57C for 4 hours, and washing with phosphate buffered saline, this? After reacting with enzyme-labeled antibody engineered gG or its F(ab')1, preferably its Fab' at 4°C to 37°C for 4 to 12 hours, preferably at 20°C for 4 hours, phosphate buffered saline was added. After washing with water, the enzyme activity bound to the solid phase was measured. Labeling enzymes include alkaline phosphatase, β-
Examples include D-galactosidase and peroxidase, with peroxidase being suitable. In addition, as the enzyme's t1, the beam IJ,'<.
ばペルオキシダーゼの場合、基1イのH!0!と共Vこ
5−アミノサリチル酸、0−フェニレンジアミン等の発
色基質、3−(p−ヒドロキシフェニル)プロピオン酸
等の蛍光基質、ルミノール等の発光基質等が用いられ、
中でも蛍光基質が適している。For example, in the case of peroxidase, H! of group 1a! 0! Chromogenic substrates such as 5-aminosalicylic acid and 0-phenylenediamine, fluorescent substrates such as 3-(p-hydroxyphenyl)propionic acid, and luminescent substrates such as luminol are used.
Among these, fluorescent substrates are suitable.
また、抗体を不溶化した固相担体、抗原、酵素標識抗体
Fab’ を同時に反応させて測定を行う一段法を行
うことも可能である。It is also possible to carry out a one-step method in which a solid phase carrier in which the antibody is insolubilized, an antigen, and an enzyme-labeled antibody Fab' are reacted simultaneously to carry out the measurement.
本発明によるハプテン測定法の場合も、上記と同様に行
うことができるが、ハブテンの場合は、本発明による(
C)工程において、従来知られている免疫学的測定法、
例えば競争結合免疫測定法を使用すればよい。In the case of the hapten measurement method according to the present invention, it can be carried out in the same manner as above, but in the case of hapten, the method according to the present invention
C) In the step, a conventionally known immunoassay method,
For example, a competitive binding immunoassay may be used.
以下、本発明を実施列により更に具体的に説明するが、
本発明はこれら実施例に限定されない。Hereinafter, the present invention will be explained in more detail with reference to examples.
The invention is not limited to these examples.
実殉例1 インスリンの測定
!(々のヒト血清α005dにα115dの緩衝液(C
1mol/l NaC2と1r/zEsAを含む10
mmo1/l リン[Na%pH7,0) f添加し、
これにα01−の3 mo1/l HOLを加えてPH
fおよそ1に合せた後、室温で60分放置した。これV
こα01−の2.9−5 mol/1)JaOHを加え
て中)口し、史にα01−の緩衝液(1,8mol/7
NaC6と5r/l BEIAと15y/1Na
N1 f含む11103m01/lリンp Na 、
pH7,0)を加えた。このようにして調整したサ
ンプル[C15−中のインスリンを公知のサンドインチ
酵素免疫測定法により測定した(K −h、ルアン(x
−h%Ruan ) ら、クリ二カ・中ミカ・アクタ
(Cl1n、Chim、Acta ) 第147巻第
167頁(1985)]。つまり、]サンプルα15−
全抗インスリン抗体結合ポリスチレンボーとまぜ、37
℃4時間反応させた。なお、抗インスリン抗体結合ポリ
スチレンボールは以下のようにして作成した。Actual case 1: Measuring insulin! (A buffer solution (C) of α115d in human serum α005d
10 containing 1 mol/l NaC2 and 1r/zEsA
mmo1/l phosphorus [Na% pH 7,0) f added,
Add 3 mo1/l HOL of α01- to this and adjust the pH
After adjusting f to approximately 1, it was left to stand at room temperature for 60 minutes. This is V
Add 2.9-5 mol/1) JaOH of α01- to the mixture, add 2.9-5 mol/1) of α01- buffer solution (1.8 mol/7
NaC6 and 5r/l BEIA and 15y/1Na
11103 m01/l phosphorus p Na including N1 f,
pH 7.0) was added. Insulin in the thus prepared sample [C15-
-h%Ruan) et al., Cl1n, Chim, Acta, Vol. 147, p. 167 (1985)]. That is, ]sample α15−
Mixed with whole anti-insulin antibody-conjugated polystyrene bow, 37
The reaction was carried out at ℃ for 4 hours. Note that the anti-insulin antibody-bound polystyrene balls were prepared as follows.
抗インスリン抗体はモルモット由来抗インスリン抗血清
(医学生物学研究所、名古屋)をNa1SO4で塩析し
DBAM−セルロースカラムクロマトグラフィーにより
精製し、抗インスリン抗体工gG k得た( K、石川
(L工shikawa ) らジャーナル・オブ・イ
ムノアッセイ(J、工mmuno −assay )第
4巻第209頁(1983)]。この抗インスリン抗体
工gGヲポリスチレンボール〔直径X 2 m (プレ
シジョン・プラスチック・ボール社、シカゴ)〕に物理
的に吸着させ不溶化させた[ K、石川及びに、加M
(K、 KatO)、 スカンジナビアン・ジャーナル
・オブーイムノロジ−(5cand、J、工mmuno
l、 )、第8巻(補遺7)第43頁(1978)]。The anti-insulin antibody was obtained by salting out guinea pig anti-insulin antiserum (Medical and Biological Research Institute, Nagoya) with Na1SO4 and purifying it by DBAM-cellulose column chromatography to obtain an anti-insulin antibody (K, Ishikawa (L)). Journal of Immunoassay, Vol. 4, p. 209 (1983)]. This anti-insulin antibody engineered gG polystyrene ball [diameter x 2 m (Precision Plastic Ball Co., Chicago). )] was physically adsorbed to make it insolubilized [ K, Ishikawa and Ni, Ka M
(K, KatO), Scandinavian Journal of Immunology (5cand, J, Engineering
), Volume 8 (Supplement 7), Page 43 (1978)].
上記サンプルと反応させた抗インスリン抗体結合ポリス
チレンボールをC1mol/1NaC2f含む10 m
mol/l リン6xqag(pHy、 o ) 2
−で洗浄後、5 nf のアフィニティーf#裏抗イン
スリンFab’−西洋ワサビ・ペルオキシダーゼ複合体
液(115mト20℃ 4時間反応させた。ベルオキシ
グーゼ標識抗インスリンFab’は以下のようにして作
成した。10 m containing anti-insulin antibody-conjugated polystyrene balls reacted with the above sample in an amount of C1 mol/1 NaC2f.
mol/l Phosphorus 6xqag (pHy, o) 2
- After washing with 5nf of affinity f# anti-insulin Fab'-horseradish peroxidase complex solution (115m), the reaction was carried out at 20°C for 4 hours. The peroxyguse-labeled anti-insulin Fab' was prepared as follows.
すなわち、上記のごとく作成されたモルモット由来抗イ
ンスリン抗体工gGからF (a b5k、 次いでF
ab’ 5r: 調Mしく前記E0石川ら、ジャーナル
・オプ・イムノアッセイ参照)、これを西洋ワサビ由来
ペルオキシダーゼ(グレード!、ベーリンガーeマンハ
イム社、マンハイム)K、N−スクシンイミジA、−6
−マレイミドヘキサノエート(同位化学研究所、熊本)
を用いて結合した後〔S、橋田(S、 I(ashid
a )ら、ジャーナル・オプ・アプライド・バイオケミ
ストリ=(J。That is, the guinea pig-derived anti-insulin antibody engineered gG to F (a b5k, then F
ab' 5r: E0 Ishikawa et al., Journal op.
-Maleimidohexanoate (Isotope Chemistry Institute, Kumamoto)
After binding using [S, Hashida (S, I(ashid
a) et al., Journal of Applied Biochemistry (J.
Appl、 Biochem、 )、第6巻第56頁(
1984)、]、メルカプトスクシニル化インスリンを
活性化チオールセファローズ4B(ファーマシア ファ
イン ケミカルス AB、ウプサラ)にカップリングさ
せたインスリン−セファローズ4Bアフイニテイーカラ
ムクロマトグラフイーにより桔製し、更にウルトロゲル
A(!A44(LKB。Appl, Biochem, ), Volume 6, Page 56 (
1984), was prepared by insulin-Sepharose 4B affinity column chromatography in which mercaptosuccinylated insulin was coupled to activated thiol Sepharose 4B (Pharmacia Fine Chemicals AB, Uppsala), and further Ultrogel A (!A44(LKB.
ストックホルム)によりfR製し、ペルオキシダーゼ標
識抗インスリンtab’を得た(前記に−hルアンらク
リニカ・キミ力・アクタ参照)。なお、酵素標識抗体の
インキュベーションに用いた緩衝液はCL 1 mol
/A NaC6とα1%B8Ai含む10 mmol
/j リン酸Na液(pH7,0)である。A peroxidase-labeled anti-insulin tab' was obtained (see Luan et al., supra). The buffer used for incubating the enzyme-labeled antibody was CL 1 mol.
/A 10 mmol containing NaC6 and α1%B8Ai
/j Sodium phosphate solution (pH 7.0).
上記のごとくインキュベートしたポリスチレンボールを
上記洗浄用緩衝液2−で洗浄後、ポリスチレンボールに
吸着したペルオキシダーゼ活性を測定した。After washing the polystyrene balls incubated as described above with the washing buffer 2-, the peroxidase activity adsorbed on the polystyrene balls was measured.
ペルオキシダーゼ活性は基質としてH2C,と3−(p
−ヒドロキシフェニル)プロピオン酸(アルドリッチ
ケミカル カンパニー インコーホレーテッド、ミルウ
オーキー)ヲ用い30℃で測定した〔今用ら、アナリテ
ィカル・レターズ(AnaL Lett、 )、第16
巻第1509頁(1983)]。蛍光強度?′11岬キ
ニン全1tのIIO5mo1/l H2BO3K溶解
した液に対する相対強度として表し、励起波長320n
m、蛍光波長a 05 nm で島津スペクトロフルオ
ロメーター(R’F−510島津製作所、京都)を用い
て測定し、標準インスリンを用いた検ffk線から試料
中のインスリン量に求めた。15種の血清サンプルの測
定結果を表1に示す。すiわち表1は本発明方法と従来
法(酸/ポリエチレングリコール処理)更に前処理なし
で測定した場合の測定結果の比較を、抗インスリン抗体
存在血清と非存在血清とで示したものである。Peroxidase activity is activated by H2C and 3-(p) as substrates.
-hydroxyphenyl)propionic acid (Aldrich
Chemical Company Incorporated (Milwaukee) at 30°C
Vol. 1509 (1983)]. Fluorescence intensity? '11 It is expressed as the relative intensity to the solution containing 1 ton of IIO5mol/l H2BO3K of Misaki Kinin, and the excitation wavelength is 320n.
The amount of insulin in the sample was determined from the ffk line measured using standard insulin. Table 1 shows the measurement results for 15 types of serum samples. In other words, Table 1 shows a comparison of the measurement results between the method of the present invention and the conventional method (acid/polyethylene glycol treatment) and without pretreatment, using serum with and without anti-insulin antibodies. be.
表 1
l−)−90155129
2+ 49 109 100
5 + 117 206 200
5+ 97 185 185
6 + 168 236 221
7 + 113 240 221
9+65167151
10 + 47 63 60
11 ノーマル 7.5 7.0
6,112 ノーマル 13
15 113 ノーマル 12
13 1314 ノーマル
13 15 1315 ノーマル
9.1 9.1 a2比較列1
従来法である酸処理とポリエチレングリコール法を組合
せた方法でインスリ/の測定を行った。すなわち種々の
ヒト血清(105−を0.01dの1 mo1/1Ho
t と混合し、室温に60分放置した後、ao 7+
dの250?/lポリエチレングリコールと混合し、α
01−の1 mol/1NaOI(を加えた後、150
0’APで45分遠心分離した(前記S、ナカガワら、
ディアベテス参照)。Table 1 l-) -90155129 2+ 49 109 100 5 + 117 206 200 5+ 97 185 185 6 + 168 236 221 7 + 113 240 221 9+65167151 10 + 47 63 60 11 No Maru 7.5 7.0
6,112 Normal 13
15 113 Normal 12
13 1314 Normal
13 15 1315 Normal
9.1 9.1 a2 Comparison Row 1 Insulin was measured using a method combining conventional acid treatment and polyethylene glycol method. That is, various human serum (1 mo1/1 Ho of 0.01 d of 105-
After mixing with t and leaving at room temperature for 60 minutes, ao 7+
d's 250? /l polyethylene glycol mixed with α
After adding 1 mol/1 NaOI of 01-, 150
Centrifuged at 0'AP for 45 minutes (S. Nakagawa et al.
(see Diabetes).
この上清α01@/を(114−の緩衝液(α42mo
l/1NaC4,1,I P/ l BSA、 1
.1 r/zNaN1 を含む10 mmol/lリ
ンp Na pH7,0)と混合した後上記のように
インスリンを測定した。結果を表1の酸/ポリエチレン
グリコール処理のカラムに示す。This supernatant α01@/ (114- buffer solution (α42mo
l/1NaC4,1,I P/l BSA, 1
.. Insulin was measured as described above after mixing with 10 mmol/l phosphate Na pH 7,0) containing 1 r/z NaN1. The results are shown in the acid/polyethylene glycol treatment column of Table 1.
表1から明らかなよって、実施列1で行った本発明によ
る測定法は、従来法同様の結果を、従来法と比べ非常に
簡便にうろことができる。As is clear from Table 1, the measurement method according to the present invention carried out in Example 1 can produce similar results to the conventional method, much more easily than the conventional method.
比Iiy!2例2
血清サンプルの前処理なしで単に実施り11で示した酵
素免疫測定法によってインスリンを測定した。結果を表
1の前処理なしのカラムに示す。この結果より血清サン
プル中に抗インスリン抗体が存在しない場合は実施例1
、比較例1と同様の結果が得られるが、抗インスリン抗
体存在下においては全サンプルにおいて実施例1、比較
列1に比べ明らかに低値を示し、抗体存在下においては
正確に抗原量を測定できないことが示される。ratio! Example 2 Insulin was measured by the enzyme immunoassay method described in Example 11 simply without pretreatment of the serum sample. The results are shown in the column without pretreatment in Table 1. From this result, if there is no anti-insulin antibody in the serum sample, Example 1
, the same results as Comparative Example 1 are obtained, but in the presence of anti-insulin antibodies, all samples show clearly lower values than in Example 1 and Comparison Row 1, and in the presence of antibodies, the antigen amount can be accurately measured. It shows that it is not possible.
以上、実施例1、比較列1及び比較列2の結果より、実
施列1で行った本発明方法によって従来法より簡便に、
抗体?含む試料中Vこおいてでさえも抗原を正確番で測
定できることが示される。As mentioned above, from the results of Example 1, Comparison Column 1, and Comparison Column 2, the method of the present invention performed in Practical Column 1 can be used more easily than the conventional method.
antibody? It is shown that the antigen can be accurately measured even in samples containing V.
実施例2 インスリンの測定
種々のヒト血清サンプル50μtに12.5μtのα5
molAHOtを加えpH6xsとした後、25μt
のデキストラン−チャコール!!テ濁it添加し、遊離
インスリンを吸着させた。この混合clJrc 5分間
、かくはんしながら反応させ、j2.5tiLのQ、
38 mol/1NaOHf加え中和し15008r
15分間遠心分it行い、この上清を同様にもう一度遠
心分mを行った。この上清の一部70μtに2μ工Uイ
ンスリンを含む35atの1 f/ L NaN1.1
.Or/ L BSA、a、 1mo1/z Na
(!を含有10 mmol/lリン酸Na(pH7,0
)を加え4℃で24時間反応させた。Example 2 Measurement of Insulin 12.5 μt of α5 in 50 μt of various human serum samples
After adding molAHOt to pH 6xs, 25μt
Dextran - Charcoal! ! It was added to the solution to adsorb free insulin. This mixture clJrc was reacted for 5 minutes with stirring, and the Q of j2.5tiL,
Add 38 mol/1 NaOHf and neutralize 15008r
The mixture was centrifuged for 15 minutes, and the supernatant was centrifuged again in the same manner. A 70 μt portion of this supernatant contains 35 at 1 f/L NaN1.1 containing 2 μg U insulin.
.. Or/L BSA, a, 1mo1/z Na
(Contains 10 mmol/l Na phosphate (pH 7,0
) was added and reacted at 4°C for 24 hours.
この反応液の一部15μtに105μtの12/l
BSA、 α1 mol/1Na(’を含有10 mm
ol/lリン酸Na (pH7,0) k加えた。この
ようKして調製したサンプル中のインスリンを実施例1
1と同様に本発明方法により測定した。15種類の血清
サンプルの測定結果及び添加インスリンの回収率を表2
に示す(本発明方法)。A portion of this reaction solution is 15 μt and 105 μt is 12/l.
BSA, α1 mol/1Na (containing 10 mm
ol/l Na phosphate (pH 7,0) was added. Example 1 Insulin in the sample prepared by K.
It was measured by the method of the present invention in the same manner as in 1. Table 2 shows the measurement results of 15 types of serum samples and the recovery rate of added insulin.
(method of the present invention).
捷た、本発明方法におけるような酸処理を行わない種々
のサンプルを測定した結果を表2の前処理なしのカラム
に示す。The results of measuring various samples that were shredded and not subjected to acid treatment as in the method of the present invention are shown in the column without pretreatment in Table 2.
表2から明らかなように、血清サンプル中に抗インスリ
ン抗体が存在しない場合は、本発明方法と前処理なしの
方法とは同様の回収率が得られた。しかし、抗インスリ
ン抗体の存在するサンプルにおいては本発明方法と比べ
、前処理なしの方法は回収率の低いものが認められる。As is clear from Table 2, when anti-insulin antibodies were not present in the serum sample, the method of the present invention and the method without pretreatment yielded similar recovery rates. However, in samples containing anti-insulin antibodies, the method without pretreatment has a lower recovery rate than the method of the present invention.
すなわち、本発明方法によって測定した場合は94〜1
02%と良好な回収率を示すが、前処理なしで測定した
場合、回収率は39〜104係となり、抗体存在下にお
いては正確な抗原量を測定できないことが示される。That is, when measured by the method of the present invention, it is 94-1
This shows a good recovery rate of 0.02%, but when measured without pretreatment, the recovery rate is between 39 and 104%, indicating that it is not possible to accurately measure the amount of antigen in the presence of antibodies.
以上の結果より、本発明方法によって、抗体を含む試料
中において抗原を正確に測定できることが示される。The above results indicate that the method of the present invention allows accurate measurement of antigens in samples containing antibodies.
以上詳細に説明したように、本発明方法によれば、従来
法に比べ、非常((簡便に、多くの種類の抗原及びハブ
テン量が、抗体存在下において測定可能となった。As explained in detail above, according to the method of the present invention, the amounts of many types of antigens and habten can be measured in the presence of antibodies with much greater ease than with conventional methods.
手 続 補 正 書 (自9.)
昭和61年9月5日
特許庁長官 黒 IB 明 雄 殿1、事件の表示
昭和61年特許頒第181955号λ発明の名称
抗原の酵1定方法
五補正をする者
事件との関係 特許出呵人
住 所 宮崎県宮崎市大塚台西3丁目24番の1氏
名 石 川 栄 治西新橋
中央ビル302号
電話(437)−3467
氏 名 弁理士(7850) 中 本
宏(ほか2名)
i補正命令の日付 自発補正
i&補正の対象 パ−、−
′(1)明細書の発明の詳細な説明の(閑、;
′、−,t□い−
2補正の内容
明細書の発明の詳細な説明の欄を下記のとおシ補正する
。Proceedings Amendment (Section 9.) September 5, 1986 Director-General of the Patent Office Akio Kuro IB 1, Indication of the case 1985 Patent Distribution No. 181955 λ Name of the invention
Relation to the Case of Person Making Amendments to Antigen Fermentation 1. Address of Patent Licensee: 1-24, 3-24 Otsukadainishi, Miyazaki City, Miyazaki Prefecture Name: Sakae Ishikawa, 302, Chisai Shinbashi Chuo Building, Telephone: (437)-3467 Name Patent Attorney (7850) Nakamoto
Hiroshi (and 2 others) i Date of correction order Voluntary correction
i & correction target par, -
'(1) Detailed explanation of the invention in the specification.
', -, t□ - 2 Contents of amendment The detailed description of the invention column in the specification will be amended as follows.
+11 明細書第5頁4行の「数十時間」を「数分〜
数十時間」と補正する。+11 Change “several tens of hours” to “several minutes to several minutes” on page 5, line 4 of the specification.
"Dozens of hours," he corrected.
Claims (1)
酸を添加し、抗原性は損わないが 該抗原又はハプテンの免疫学的測定に影響 を及ぼす抗体を酸性条件下で失活させる工 程 (B)該被検液を中和する工程 (C)該被検液中の抗原又はハプテン量を免疫学的に測
定する工程 を包含することを特徴とする抗原又はハプテンの測定方
法。[Claims] 1. The following steps (A), (B) and (C) (A) Adding an acid to a test solution containing an antigen or hapten and its antibody, but not impairing antigenicity. (B) neutralizing the test solution; (C) reducing the amount of the antigen or hapten in the test solution by immunization. 1. A method for measuring an antigen or hapten, comprising a step of chemically measuring it.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61181933A JPH0792454B2 (en) | 1986-08-04 | 1986-08-04 | Antigen measurement method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61181933A JPH0792454B2 (en) | 1986-08-04 | 1986-08-04 | Antigen measurement method |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6338163A true JPS6338163A (en) | 1988-02-18 |
JPH0792454B2 JPH0792454B2 (en) | 1995-10-09 |
Family
ID=16109431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61181933A Expired - Lifetime JPH0792454B2 (en) | 1986-08-04 | 1986-08-04 | Antigen measurement method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0792454B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63200064A (en) * | 1987-02-17 | 1988-08-18 | Mitsubishi Kasei Corp | Measuring method of antigen-antibody reaction |
JPH08145998A (en) * | 1994-11-15 | 1996-06-07 | Daiichi Rajio Isotope Kenkyusho:Kk | Immunological measuring method of insulin-like growth factor, and kit for measuring the factor |
WO2018212221A1 (en) * | 2017-05-17 | 2018-11-22 | 富士レビオ株式会社 | Insulin measurement method and measurement reagent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56126763A (en) * | 1980-02-08 | 1981-10-05 | Hoffmann La Roche | Pretreatment of human ceram and plasma sample |
-
1986
- 1986-08-04 JP JP61181933A patent/JPH0792454B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56126763A (en) * | 1980-02-08 | 1981-10-05 | Hoffmann La Roche | Pretreatment of human ceram and plasma sample |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63200064A (en) * | 1987-02-17 | 1988-08-18 | Mitsubishi Kasei Corp | Measuring method of antigen-antibody reaction |
JPH08145998A (en) * | 1994-11-15 | 1996-06-07 | Daiichi Rajio Isotope Kenkyusho:Kk | Immunological measuring method of insulin-like growth factor, and kit for measuring the factor |
WO2018212221A1 (en) * | 2017-05-17 | 2018-11-22 | 富士レビオ株式会社 | Insulin measurement method and measurement reagent |
JPWO2018212221A1 (en) * | 2017-05-17 | 2020-03-19 | 富士レビオ株式会社 | Insulin measuring method and measuring reagent |
Also Published As
Publication number | Publication date |
---|---|
JPH0792454B2 (en) | 1995-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5262296A (en) | Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition | |
EP0177531B1 (en) | Antibodies, manufacture and use | |
US4828985A (en) | Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods | |
GB2074727A (en) | Immunological diagnostic method | |
US4670383A (en) | Immune-chemical measurement process for haptens and proteins | |
JPS5972059A (en) | Method of examining antigen and examining tool | |
EP0724726B1 (en) | Method for the determination of an analyte and its use for the determination of anti-tsh receptor autoantibodies in a patient serum | |
EP0217542A1 (en) | Diagnostic test drug comprising monoclonal antibody to human copper zinc-superoxide dismutase and diagnostic test method using the same | |
Van Steirteghem et al. | Radioimmunoassay of creatine kinase isoenzymes in human serum: isoenzyme MM. | |
JPS6338163A (en) | Method for measuring antigen | |
EP0538430A1 (en) | Endometrial antigen, composition, test kit and method for endometrial antibody determination | |
JPH0198968A (en) | How to measure His insulin | |
JPH03170058A (en) | Reagent complex for immunoassay | |
US4900661A (en) | Method for immunological determination of amines, monoclonal antibodies and kit of reagents for carrying out the method | |
EP0210863A1 (en) | Immunoassay | |
JP3709078B2 (en) | Method and kit for measuring diacetylpolyamine | |
EP0085402B1 (en) | Method of determination of human urine kallikrein and kit for the same | |
JPS583671B2 (en) | Methods of increasing the ability of apoglucose oxidase to bind flavin adenine dinucleotide and its derivatives, homogeneous specific binding assays, homogeneous immunoassays for measuring complexes and ligands in liquid media, Reagents and | |
JPH07313186A (en) | Anti-pivka-ii monoclonal antibody | |
JP2878317B2 (en) | Laminin measurement reagent | |
JPH0313864A (en) | Measuring method of tnf-alpha, kit and method of diagnosis | |
Yakubova et al. | ELISA: METHODS, PRINCIPLES AND APPLICATION | |
JPH05296999A (en) | Human lipocortin i as marker for discriminating effect of flucocorticoid and its determining method | |
JPS62184353A (en) | Immunochemical measurement method for human epithelia cell growth factor and kit for said method | |
JPS6247554A (en) | Immunochemical measuring method of human epithelia cell growing factor and kit thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |